Phase 4CompletedINTERVENTIONAL
Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria
ClinicalTrials.gov · NCT03331289 · Registry updated: 2023-07-24
- Condition / research focus
- Diabetes Mellitus, Type 2
- Sponsor
- The University of Texas Health Science Center at San Antonio
- Countries with listed sites
- United States
- Registry dates and results
- Start: 2018-02-28. Completion: 2022-11-04 (may be estimated). Results are posted in this registry.
Products and interventions (4)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- Placebo (drug) — also listed as: Placebo drug
- Exenatide (drug) — also listed as: Byetta, Bydureon
- Dapagliflozin (drug) — also listed as: Farxiga
- Exenatide and Dapagliflozin (drug) — also listed as: Byetta plus Dapagliflozin
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- University Health System Texas Diabetic Institute
San Antonio, Texas, United States
Site recruitment: Not reported